Prof. Biyun Wang 王碧芸
Chief Physician, Professor
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of breast cancer, including chemotherapy, endocrine therapy, and molecular targeted therapy. Experienced in managing recurrent and refractory breast cancer.
Dr. Wang is a Chief Physician, Professor, and Master’s Supervisor, leading the Breast and Urologic Oncology group. After graduating from Shanghai Medical University (now Fudan University Medical College) in 1998, Dr. Wang joined the Department of Medical Oncology at Fudan University Shanghai Cancer Center. Promotions followed: Attending Physician in 2004, Associate Chief Physician in 2009, and Chief Physician in 2017.
Professional roles
- Vice Chair, CSCO Young Experts Committee
- Standing Committee Member, Breast Cancer Professional Committee, Chinese Research Hospital Association
- Member, Breast Cancer Expert Committee, CSCO
- Standing Committee Member and Secretary-General, Shanghai CRPC
Name order: in Chinese the family name comes first (Wang Biyun). Papers usually list the name as Biyun Wang or Wang B.
Selected publications
125 papers on PubMed matched by name and affiliation; 33 as first or senior author since 2016. Most recent first- or senior-author papers:
- Eur J Nucl Med Mol Imaging, 2026 (senior author): Real-world application of (18)F-FES PET/CT on HR + breast cancer patients with brain metastases. PubMed 41275454
- Ther Adv Med Oncol, 2026 (senior author): Effectiveness, safety, and biomarker analysis of sacituzumab govitecan in Chinese metastatic breast cancer: a multicenter real-world study. PubMed 41908795
- Ther Adv Med Oncol, 2025 (senior author): Development and validation of nomograms of outcomes for first-line platinum-based chemotherapy for metastatic triple-negative breast cancer: patient-level analysis of five prospective clinical trials in China. PubMed 41280131
- Nat Commun, 2025 (senior author): Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs. PubMed 41184255
- Ther Adv Med Oncol, 2025 (senior author): Efficacy and safety of utidelone in pretreated patients with metastatic breast cancer in China: a multicenter, real-world study. PubMed 40900679
- Transl Breast Cancer Res, 2025 (senior author): Precision diagnosis and treatment of PI3K/AKT/PTEN signaling pathway in HR-positive advanced breast cancer: perspectives from Chinese experts. PubMed 41210646
- Breast Cancer Res, 2025 (first author): 8MW0511, a novel, long-acting granulocyte-colony stimulating factor fusion protein for the prevention of chemotherapy-induced neutropenia: final results from the phase III clinical trial. PubMed 40329331
- Ther Adv Med Oncol, 2024 (senior author): Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2-metastatic breast cancer patients: a multicenter study (YOUNGBC-28). PubMed 39697620
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion